ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Plans CHF500 Million New Manufacturing Facility

ZURICH -(Dow Jones)- Swiss pharmaceutical company Novartis AG (NVS) said Monday it is planning to invest over 500 million Swiss francs ($550 million) building a new manufacturing facility in Switzerland. MAIN FACTS: -The company said the investment underlines the long-term strategy of Novartis to establish a worldwide manufacturing network of technology centers. -The new production site in Stein, Switzerland, is expected to be fully operational by end of 2016. -"This investment is further strengthening the importance of Stein as Manufacturing Center of Excellence for sterile and solid dosage forms and will play a key role in our global production network," said Joseph Jimenez, CEO of Novartis. "It also strengthens our presence in Switzerland, which remains a center of key importance for Novartis." -The Stein site in Canton Aargau is the largest production facility of the Pharmaceuticals Division. Every year, the approximately 1,400 associates at the site produce over 4.1 billion tablets, capsules, ampoules, prefilled syringes, vials and transdermal therapeutic systems, which are exported to over 150 countries. -The new set-up will allow Novartis to adapt its production capacity more quickly depending on an evolving portfolio and market demand. The center will serve approximately 150 markets globally. -Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/17/201513:02:02Could This Be Healthcare's $158 Billion Black Swan Event?
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201515:04:02GlaxoSmithKline PLC Earnings: Pay No Attention to the Results...
05/08/201511:12:03The Best Fidelity Mutual Funds
05/07/201513:40:20Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/07/201513:34:24Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/06/201518:01:31ADR Shares End Mixed; Anheuser-Busch InBev Rises
05/06/201508:50:06GSK Cuts Return to Holders From Novartis Asset Swap
05/06/201507:58:20Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million
05/04/201519:22:23Generic Drugs Grab Growing Market Share in Mexico--Update
05/04/201519:22:11Generic Drugs Grab Market Share in Mexico
05/04/201511:57:01Why Shares in Array BioPharma, Inc. Are Soaring Higher
05/02/201510:41:02The Best Way to Invest Money in Silicon Valley
05/01/201514:49:19Waiting for Exelixis, Inc.'s Meteor to Land
04/30/201513:47:19Teva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays...
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad